A5010061250- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Family Support in Illness
- Cancer survivorship and care
- Protein Degradation and Inhibitors
- Neuroblastoma Research and Treatments
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Multiple and Secondary Primary Cancers
- Palliative Care and End-of-Life Issues
- Renal Transplantation Outcomes and Treatments
- Frailty in Older Adults
- Economic and Financial Impacts of Cancer
- Quinazolinone synthesis and applications
- Cell Adhesion Molecules Research
University of Alabama at Birmingham
2016-2025
The University of Texas Southwestern Medical Center
2024-2025
Southwestern Medical Center
2025
Manchester Academic Health Science Centre
2025
University of Manchester
2024-2025
University of Michigan
2006-2025
Medi-Caps University
2025
Children's National
2003-2024
George Washington University
2024
O'Neal Comprehensive Cancer Center
2020-2024
Older adults are vulnerable to chemotherapy toxicity; however, there limited data identify those at risk. The goals of this study risk factors for toxicity in older and develop a stratification schema toxicity.Patients age ≥ 65 years with cancer from seven institutions completed prechemotherapy assessment that captured sociodemographics, tumor/treatment variables, laboratory test results, geriatric variables (function, comorbidity, cognition, psychological state, social activity/support,...
We present an update of a previously reported Late Effects Study Group cohort 1,380 children with Hodgkin's disease (HD) diagnosed between 1955 and 1986 in patients aged 16 years or younger. describe the pattern incidence subsequent neoplasms (SNs) occurring extended follow-up.Median age at diagnosis HD was 11.7 (range, 0.3 to 16.9 years) last follow-up 27.8 years. Median length 17.0 years.An additional 103 SNs were ascertained (total = 212). The 18.5-fold increased risk developing compared...
Over the past several decades, number of cancer survivors has increased dramatically as a result improved early detection first malignancies and effective therapies. There are more than 13 million in United States today.1 This is expected to reach 18 by 2022.1 These data underscore public health magnitude survivorship importance efforts characterize address concerns survivors. Although population heterogeneous, many face distinct serious care issues. Cancer at risk for long-term morbidity...
Purpose Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by somatic mutations in the blood otherwise healthy adults. We hypothesized that patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma, CHIP at time ASCT would be associated with increased risk myelodysplastic syndrome and acute myeloid leukemia, collectively termed therapy-related neoplasm (TMN), other adverse outcomes. Methods performed whole-exome sequencing on...
Purpose Philadelphia chromosome (Ph) –like acute lymphoblastic leukemia (ALL) is a high-risk subtype of childhood ALL characterized by kinase-activating alterations that are amenable to treatment with tyrosine kinase inhibitors. We sought define the prevalence and genomic landscape Ph-like in adults assess response conventional chemotherapy. Patients Methods The frequency was assessed gene expression profiling 798 patients B-cell age 21 86 years. Event-free survival overall were determined...
Age has long been used as a major factor for assessing suitability allogeneic hematopoietic cell transplantation (HCT). The HCT-comorbidity index (HCT-CI) was developed measure of health status to predict mortality risk after HCT. Whether age, comorbidities, or both should guide decision making HCT is unknown.Data from 3,033 consecutive recipients HLA-matched grafts five institutions contributed this analysis. Patients were randomly divided into training set develop weights age intervals and...
Little is known about how leukemia cells alter the bone marrow (BM) niche to facilitate their own growth and evade chemotherapy. Here, we provide evidence that acute myeloid (AML) blasts remodel BM into a growth-permissive normal hematopoiesis-suppressive microenvironment through exosome secretion. Either engrafted AML or AML-derived exosomes increased mesenchymal stromal progenitors blocked osteolineage development formation in vivo. Preconditioning with 'primed' animals for accelerated...
We characterized leukemia stem cells (LSC) in chronic phase myelogenous (CML) using a transgenic mouse model. LSC were restricted to with long-term hematopoietic cell (LTHSC) phenotype. CML LTHSC demonstrated reduced homing and retention the bone marrow (BM), related decreased CXCL12 expression BM, resulting from increased G-CSF production by cells. Altered cytokine BM was associated selective impairment of normal growth advantage LTHSC. Imatinib (IM) treatment partially corrected...
Carbonyl reductases (CBRs) catalyze reduction of anthracyclines to cardiotoxic alcohol metabolites. Polymorphisms in CBR1 and CBR3 influence synthesis these We examined whether single nucleotide polymorphisms (CBR1 1096G>A) and/or (CBR3 V244M) modified the dose-dependent risk anthracycline-related cardiomyopathy childhood cancer survivors.One hundred seventy survivors with (patient cases) were compared 317 no (controls; matched on diagnosis, year length follow-up, race/ethnicity) using...
The risk of breast cancer is high in women treated for a childhood with chest irradiation. We sought to examine variations resulting from irradiation field and radiation dose.
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, blast phase) usually diagnosed chronic phase. Tyrosine kinase inhibitor (TKI) therapy highly effective first-line treatment option for all patients with newly phase (CP-CML). The selection TKI should be based on risk score,...
Abstract Chromosomal rearrangements are initiating events in acute lymphoblastic leukaemia (ALL). Here using RNA sequencing of 560 ALL cases, we identify between MEF2D (myocyte enhancer factor 2D) and five genes ( BCL9 , CSF1R DAZAP1 HNRNPUL1 SS18 ) 22 B progenitor (B-ALL) cases with a distinct gene expression profile, the most common which is MEF2D-BCL9 . Examination an extended cohort 1,164 B-ALL identified 30 rearrangements, include additional fusion partner, FOXJ2 ; thus, MEF2D-...